Pliant Therapeutics, Inc. (PLRX) News
Track canonical SquawkNews coverage tagged to PLRX, Pliant Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Pliant Therapeutics gets FDA Fast Track for PLN-101095 plus pembrolizumab
Pliant Therapeutics (PLRX) receives FDA Fast Track designation for PLN-101095 when used in combination with pembrolizumab to treat ICI-refractory solid tumors.
REGULATION | Aug 18, 2026, 12:30 PM UTC
L
Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate
Pliant Therapeutics (NASDAQ: PLRX ) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share
EARNINGS | Aug 11, 2026, 08:21 PM UTC
L
PLRX - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PLRX - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 11, 2026, 08:07 PM UTC